6-Mercaptopurine, which targets phosphoribosyl pyrophosphate aminotransferase during purine synthesis, is currently used to treat patients with ALL, while both enasidenib and ivosidenib affect 2-hydroxyglutarate synthesis (targeting IDH2 and IDH1) and are both approved for acute myeloid leukemia (AML) [176, 177]. Here, IDH2 is linked to acute myeloid leukemia.